Keytruda (pembrolizumab)

pCPA File Number: 21386
Negotiation Status:
Concluded with an LOI
Indication(s):
Head and Neck Squamous Cell Carcinoma (HNSCC)
Sponsor/Manufacturer:
Merck Canada Inc.
CADTH Project Number:
pCODR 10216
pCPA Engagement Letter Issued:
Negotiation Process Concluded: